Medy-Tox Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 03:39 am
Share
Medy-Tox Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported negative sales was KRW 0.00026 million compared to KRW 0.00022 million a year ago. Net loss was KRW 2,322.28 million compared to net income of KRW 13,208.03 million a year ago. Basic loss per share from continuing operations was KRW 353 compared to basic earnings per share from continuing operations of KRW 2,098.0952 a year ago. Basic loss per share was KRW 353 compared to basic earnings per share of KRW 2,203 a year ago.
For the nine months, sales was KRW 0.00002 million compared to negative sales of KRW 0.00026 million a year ago. Net income was KRW 11,803.39 million compared to KRW 37,491.73 million a year ago. Basic earnings per share from continuing operations was KRW 1,620 compared to KRW 6,075 a year ago. Basic earnings per share was KRW 1,620 compared to KRW 6,075 a year ago.
Medy Tox Inc is a Korea-based company engaged in the development, manufacture and marketing of biopharmaceuticals. The Companyâs main product is type A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. Its products are also used in chin plastic surgeries. The Company provides its products under the brand names of Medytoxin, Neurox, Siax, and Neuramis. In addition, the Company develops and sells medical devices such as injectors under the brand names of Neurajet, Neurafen and others. The Company also engages in technology transfer. The Company distributes its products in domestic and overseas markets such as Japan, China, Russia and Europe.
MEDY-TOX INC. 
